Progress in the development of HPV vaccine

Infections in Medicine

Volumn 14, Issue 7, 1997, Pages

  Hagensee, Michael E ^a,b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Section of Infectious Diseases   (United States)

Author keywords

Cervical cancer; DNA tumor virus; Genital warts; Human papillomavirus; Immunoassays; Immunosuppression; Vaccines

Indexed keywords

ALPHA INTERFERON; ALPHAN3 INTERFERON; LIQUID NITROGEN; POD BEN; PODOLIN; PODOPHYLLIN; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; STRUCTURAL PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS VACCINE;

ANUS CANCER; CLINICAL TRIAL; CONDYLOMA; HUMAN; LASER SURGERY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; SKIN CANCER; UTERINE CERVIX CANCER; VERRUCA PLANTARIS; VERRUCA VULGARIS; VIRUS GENOME; VIRUS PARTICLE; WART VIRUS;

EID: 0030825870     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Koustky LA, Galloway DA, Holmes KK: Epidemiology of genital human papillomavirus infection. Epidemiol Rev 10:122-163, 1988.
2. zur Hausen H: Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 184:9-13, 1991.
3. Orth G, Favre M, Croissant O: Characterization of a new type of human papillomavirus that causes skin warts. J Virol 24:103-120, 1977.
4. de Villiers EM, Gissman L, zur Hausen H: Molecular cloning of viral DNA from human genital warts. J Virol 40:932-935, 1981.
5. Gissman L, Wolnik L, Ikenberg H, et al: Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc Natl Acad Sci U S A 80:560-563, 1983.
6. Brown DR, Bryan JT, Cramer H, et al: Analysis of human papillomavirus types in exophytic condylomata acuminata by hybrid capture and Southern blot techniques. J Clin Micro 31:2667-2673, 1993.
7. Ostrow R, Bender M, Nimura M, et al: Human papillomavirus DNA in cutaneous primary and metastasized squamous cell carcinomas from patients with epidermodysplasia verruciformis. Proc Natl Acad Sci U S A 79:1634-1638, 1982.
8. Phelps, WC, Alexander, KA: Antiviral therapy for human papillomaviruses: Rationale and prospects. Ann Intern Med 123:368-382, 1995.
9. Nuovo GJ, Blanco JS, Leipzig S, et al: Human papillomavirus detection in cervical lesions nondiagnostic for cervical intraepithelial neoplasia: Correlation with Papanicolaou smear, colpolscopy, and occurrence of cervical intraepithelial neoplasia. Obstet Gyncol 75:1006-1011, 1990.
10. Diagnostic and therapeutic technology assessment: Human papillomavirus DNA testing in the management of cervical neoplasia. JAMA 270:2975-2981, 1993.
11. Centers for Disease Control and Prevention: Condyloma acuminatum - United States, 1966-1981. MMWR 32:306-308, 1983.
12. zur Hausen H: Viruses in human cancer. Science 254:1167-1173, 1991.
13. Schiffman MH: Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 84:394-398, 1992.
14. Munoz N, Bosch FX: Epidemiology of cervical cancer, in Munoz N, Bosch FX, Jensen OM (eds): Human Papillomaviruses and Cervical Cancer. Lyon, IARC Scientific Publications, 1989, pp 9-40.
15. Cason J, Khan SA, Best JM: Towards vaccines against human papillomavirus type-16 genital infections. Vaccine 11:603-611, 1993.
16. zur Hausen H: Intracellular surveillance of persisting viral infection: Human genital cancer results from deficient cellular control of papillomavirus gene expression. Lancet 2:489-491, 1986.
17. Cannistra SA, Niloff JM: Cancer of the uterine cervix. N Engl J Med 334:1030-1038, 1996.
18. Korn AP: Interpretation of abnormal Pap smears. Infect Med 13:405-406, 409-413, 1996.
19. Centers for Disease Control and Prevention: Results from the National Breast and Cervical Cancer Early Detection Program, October 31, 1991-September 30, 1993. MMWR 43:530-534, 1994.
20. Benton C, Shahidullah H, Hunter JA: Human papillomavirus in the immunosuppressed. Papillomavirus Report 3:23-26, 1992.
21. Palefksy J: Human papillomavirus infection among HIV-infected individuals. Hematol Oncol Clin North Am 5:357-370, 1991.
22. Daling JR, Weiss NS, Hislop TG, et al: Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med 317:973-977, 1987.
23. Kiviat NB, Critchlow CW, Holmes KK, et al: Association of anal dysplasia and human papillomavirus with immunosuppression and HIV infection among homosexual men. AIDS 7:43-49, 1993.
24. Reichman RC, Oakes D, Bonnez W, et al: Treatment of condyloma acuminatum with three different interferons administered intralesionally: A double-blind, placebo-controlled trial. Ann Intern Med 108:675-679, 1988.
25. Leventhal BG, Kashima HK, Mounts P, et al: Long-term response of recurrent respiratory papillomatosis to treatment with lymphoblastoid interferon alfa-n1. N Engl J Med 325:613-617, 1991.
26. Reichman RC, Oakes D, Bonnez W, et al: Treatment of condyloma acuminatum with three different interferon-alpha preparations administered parenterally: A double-blind, placebo-controlled trial. J Infect Dis 162:1270-1276, 1990.
27. Jordan M: Treatment of CIN by destruction, in Jordan JA, Sharp F, Singer A (eds): Preclinical Neoplasia of the Cervix. London, Royal College of Obstetricians and Gynaecologists, 1982, pp 185-186.
28. Scheffner M, Werness BA, Huibregtse JM, et al: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136, 1990.
29. Dyson N, Howley PM, Munger K, et al: The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934-937, 1989.
30. Schwarz E, Freese UK, Gissman L, et al: Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature (London) 314:111-114, 1985.
31. Baay MFD, Duk JM, Burger MPM, et al: Antibodies to human papillomavirus type 16 E7 related to clinicopathological data in patients with cervical carcinoma. J Clin Pathol 48:410-414, 1995.
32. Stoler MH, Whitbeck A, Wolinsky SM, et al: Infectious cycle of human papillomavirus type 11 in human foreskin xenografts in nude mice. J Virol 64:3310-3318, 1990.
33. Brown D, Fan L, Jones J, et al: Colocalization of human papillomavirus type 11 E1, E4 and L1 proteins in human foreskin implants grown in athymic mice. Virology 201:46-54, 1994.
34. Kirnbauer R, Booy F, Cheng N, et al: Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 89:12180-12184, 1992.
35. Hagensee ME, Yaegashi N, Galloway DA: Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 67:315-322, 1993.
36. Rose RC, Bonnez W, Reichman RC, et al: Expression of human papillomavirus type 11 L1 protein in insect cells: In vivo and in vitro assembly of virus-like particles. J Virol 67:1936-1944, 1993.
37. Hoffman KJ, Cook JC, Joyce JG, et al: Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae. Virology 209:506-518, 1995.
38. Hagensee M, Olson N, Baker TS, et al: Three-dimensional structural analysis of vaccinia virus-produced HPV-1 capsids. J Virol 68:4503-4505, 1994.
39. Carter JJ, Wipf, G, Hagensee ME, et al: Use of human papillomavirus type 6 capsids produced by recombinant vaccinia viruses in ELISA to detect antibodies in people with genital warts. J Infect Dis 172:11-18, 1995.
40. Rose RC, Reichman RC, Bonnez W: Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol 75:2075-2079, 1994.
41. Kirnbauer R, Hubbert NL, Wheeler CM, et al: A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 86:494-499, 1994.
42. Nonnemacher B, Hubbert NL, Kirnbauer R, et al: Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV 16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain. J Infect Dis 172:19-24, 1995.
43. Carter JJ, Koutsky LA, Wipf GC, et al: The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 174:927-936, 1996.
44. Wideroff L, Schiffman MH, Hoover R, et al: Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and -negative women. J Infect Dis 174:937-943, 1996.
45. Christensen ND, Krieder JW, Shah KV, et al: Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions. J Gen Virol 73: 1261-1267, 1992.
46. Bosch FX, Manos MM, Munoz N, et al: Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J Natl Cancer Inst 87:796-802, 1995.
47. Wang Z, Hansson B, Forslund O, et al: Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA. J Clin Microbiol 34:3056-3062, 1996.
48. Hagensee ME, Koutsky L, Lee S, et al: Detection of cervical antibodies against HPV 16 capsids in a cohort of university women. In preparation.
49. Brandsma JL: Animal models for human papillomavirus vaccine development, in Lacey C (ed): Papillomavirus Review: Current Research on Papillomaviruses. Leeds, Leeds Medical Information, 1996, pp 69-78.
50. Gaukroger JM, Bradley A, Chandrachud L, et al: Interaction between bovine papillomavirus type 4 and cocarcinogens in the production of malignant tumours. J Gen Virol 74:2275-2280, 1993.
51. Pilacinski WP, Glassman DL, Glassman KF, et al: Immunization against bovine papillomavirus infection. Ciba Found Symp 120: 136-156, 1986.
52. Jarrett WFH, O'Neil BW, Gaukroger JM, et al: Studies on vaccination against papillomaviruses: The immunity after infection and vaccination with bovine papillomaviruses of different types. Vet Rec 126:473-475, 1990.
53. Jarrett WFH, Smith KT, O'Neil BW, et al: Studies on vaccination against papillomaviruses: Prophylactic and therapeutic vaccination with recombinant structural proteins. Virology 184:33-42, 1991.
54. Campo, MS, Gridlay GJ, O'Neill BW, et al: Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J Gen Virol 74:945-953, 1993.
55. Shope, RE: Infectious papillomatosis of rabbits: With a note on the histology. J Exp Med 58:607-624, 1933.
56. Christensen ND, Krieder JW, Kan NC, et al: The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology 181:572-579, 1991.
57. Lin Y, Borenstein LA, Selvakumar R, et al: Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology 187:612-619, 1992.
58. Lin Y, Borenstein LA, Ahmed R, et al: Cottontail rabbit papillomavirus L1 protein-based vaccines: Protection is only achieved with a full-length, nondenatured product. J Virol 67:4154-4162, 1993.
59. Christensen ND, Reed CA, Cladel NM, et al: Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 70:960-965, 1996.
60. Donnelly JJ, Martinez D, Jansen KU, et al: Protection against papillomavirus with a polynucleolide vaccine. J Infect Dis 713:314-320, 1996.
61. Selvakumar R, Ahmed R, Wettstein FO: Tumor regression is associated with a specific immune response to the E2 protein of cottontail rabbit papillomavirus. Virology 208:298-302, 1995.
62. Selvakumar R, Borenstein LA, Lin Y, et al: Immunization with nonstructural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas. J Virol 69:602-605, 1995.
63. Suzich JA, Ghim S, Palmer-Hill FJ, et al: Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 92:11553-11557, 1995.
64. Ostrow R, McGlennen RC, Shaver MS, et al: A rhesus monkey model for sexual transmission of a papillomavirus isolated from a squamous cell carcinoma. Proc Natl Acad Sci U S A 87:8170-8174, 1990.
65. Krieder JW, Howett MK, Leure-Dupree AE, et al: Laboratory production in vivo of infectious human papillomavirus type 11. J Virol 61:590-593, 1987.
66. Bonnez W, Rose RC, Da Rin C, et al: Propagation of human papillomavirus type 11 in human xenografts using the severe combined immunodeficiency (SCID) mouse and comparison to the nude mouse model. Virology 197:455-458, 1993.
67. Christensen ND, Kreider JW: Antibody-mediated neutralization in vivo of infectious papillomaviruses. J Virol 64:3151-3156, 1990.
68. Christensen ND, Krieder JW, Cladel NM, et al: Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11. J Virol 64:5678-5681, 1990.
69. Chen L, Thomas EK, Hu S, et al: Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci U S A 88:110-114, 1991.
70. Chen L, Mizuno MT, Singhal MC, et al: Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunology 148:2617-2621, 1992.
71. Hanissian, J: Emerging HPV vaccines. Infect Med 14:266,273-275,330, 1997.
72. Borysiewicz LK, Flander A, Nimako M, et al: A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347:1523-1527, 1996.